Reaction
Ureaplasma Infection reporting signals
As of the last recalculation, Ureaplasma Infection appears in 399 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is BASILIXIMAB (PRR 259.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Basiliximab | 51 | 259.2 | 260.4 |
| Valganciclovir Hydrochloride Powder, | 31 | 143.7 | 144.0 |
| Ganciclovir | 19 | 101.6 | 101.8 |
| Ganciclovir Sodium | 19 | 98.3 | 98.5 |
| Valganciclovir | 32 | 96.2 | 96.3 |
| Valganciclovir Hydrochloride | 32 | 96.2 | 96.3 |
| Tacrolimus Ointment 0.1% | 130 | 80.3 | 80.4 |
| Tacrolimus Extended-Release Capsules | 130 | 80.1 | 80.2 |
| Amphotericin B | 17 | 73.9 | 74.0 |
| Mycophenilic Acid | 26 | 69.9 | 70.0 |
| Tacrolimus | 133 | 65.9 | 66.0 |
| Posaconazole Delayed-Release | 13 | 63.8 | 63.9 |
| Melphalan | 25 | 61.1 | 61.2 |
| Melphalan Hydrochloride | 25 | 55.4 | 55.5 |
| Mycophenolate Mofetil | 102 | 52.3 | 52.3 |
| Mycophenolate Mofetil Hydrochloride | 102 | 52.2 | 52.2 |
| Rituximab | 134 | 49.3 | 49.3 |
| Bupivacaine | 8 | 45.6 | 45.6 |
| Mycophenolic Acid | 26 | 45.3 | 45.3 |
| Posaconazole | 13 | 43.1 | 43.1 |
| Voriconazole Injection | 17 | 42.6 | 42.6 |
| Cefepime | 11 | 41.1 | 41.2 |
| Fludarabine Phosphate | 28 | 39.9 | 39.9 |
| Cefepime Hydrochloride | 11 | 36.6 | 36.6 |
| Meropenem | 21 | 36.0 | 36.0 |
| Rifaximin | 12 | 30.8 | 30.8 |
| Voriconazole | 17 | 30.4 | 30.5 |
| Pegaspargase | 7 | 30.3 | 30.4 |
| Daptomycin | 5 | 28.6 | 28.6 |